Product Description
PF-03654764 should reduce the symptoms of allergic rhinitis (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01033396)
Mechanisms of Action: H3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Rhinitis, Allergic
Phase 1: Healthy Volunteers